London, UK – GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, today announced the completion of the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to global pharmaceutical major Lupin Limited (“Lupin”).
GHO created VISUfarma in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A. Over the course of its investment, GHO transformed the company from a domestic Italian ophthalmic player into a pan-European leader with an established commercial footprint across Italy, the UK, Spain, Germany and France, a robust portfolio of 60+ branded ophthalmology products, and revenues of €53m in 2025. This growth was underpinned by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight across each of its core territories.
Lupin’s acquisition of VISUfarma enhances its ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.
